Pregabalin 1A Farma 50 mg Kapsel, hård Svédország - svéd - Läkemedelsverket (Medical Products Agency)

pregabalin 1a farma 50 mg kapsel, hård

1a farma a/s - pregabalin - kapsel, hård - 50 mg - pregabalin 50 mg aktiv substans; mannitol hjälpämne; propylenglykol hjälpämne

Pregabalin 1A Farma 225 mg Kapsel, hård Svédország - svéd - Läkemedelsverket (Medical Products Agency)

pregabalin 1a farma 225 mg kapsel, hård

1a farma a/s - pregabalin - kapsel, hård - 225 mg - mannitol hjälpämne; pregabalin 225 mg aktiv substans; propylenglykol hjälpämne

Pregabalin 1A Farma 100 mg Kapsel, hård Svédország - svéd - Läkemedelsverket (Medical Products Agency)

pregabalin 1a farma 100 mg kapsel, hård

1a farma a/s - pregabalin - kapsel, hård - 100 mg - mannitol hjälpämne; pregabalin 100 mg aktiv substans; propylenglykol hjälpämne

Pregabalin 1A Farma 25 mg Kapsel, hård Svédország - svéd - Läkemedelsverket (Medical Products Agency)

pregabalin 1a farma 25 mg kapsel, hård

1a farma a/s - pregabalin - kapsel, hård - 25 mg - mannitol hjälpämne; pregabalin 25 mg aktiv substans; propylenglykol hjälpämne

Vitaros 2 mg/g Kräm Svédország - svéd - Läkemedelsverket (Medical Products Agency)

vitaros 2 mg/g kräm

the simple pharma company limited - alprostadil - kräm - 2 mg/g - etanol, vattenfri hjälpämne; alprostadil 2 mg aktiv substans - alprostadil

Vitaros 3 mg/g Kräm Svédország - svéd - Läkemedelsverket (Medical Products Agency)

vitaros 3 mg/g kräm

the simple pharma company limited - alprostadil - kräm - 3 mg/g - etanol, vattenfri hjälpämne; alprostadil 3 mg aktiv substans - alprostadil

Benlysta Európai Unió - svéd - EMA (European Medicines Agency)

benlysta

glaxosmithkline (ireland) limited - belimumab - lupus erythematosus, systemic - immunsuppressiva - benlysta är indicerat som tillägg på terapi hos patienter i åldern 5 år och äldre med aktiva, positiva autoantikroppar systemisk lupus erythematosus (sle) med en hög grad av sjukdomsaktivitet (e. positiv anti-dsdna och låg komplement) trots standardbehandling. benlysta is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.

Kalydeco Európai Unió - svéd - EMA (European Medicines Agency)

kalydeco

vertex pharmaceuticals (ireland) limited - ivacaftor - cystisk fibros - andra andningsorganprodukter - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 och 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 och 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Sivextro Európai Unió - svéd - EMA (European Medicines Agency)

sivextro

merck sharp & dohme b.v. - tedizolid fosfat - soft tissue infections; skin diseases, bacterial - antibacterials for systemic use, , other antibacterials - sivextro is indicated for the treatment of acute bacterial skin and skin structure infections (absssi) in adults and adolescents 12 years of age and older.

Testavan 20 mg/g Transdermal gel Svédország - svéd - Läkemedelsverket (Medical Products Agency)

testavan 20 mg/g transdermal gel

the simple pharma company limited - testosteron - transdermal gel - 20 mg/g - testosteron 20 mg aktiv substans; propylenglykol hjälpämne; etanol, vattenfri hjälpämne